Mizuho Securities Maintains CVS Health(CVS.US) With Buy Rating, Announces Target Price $58
Mizuho Adjusts Price Target on CVS Health to $58 From $66, Keeps Outperform Rating
TD Cowen Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $80
CVS Health: Strategic Buy Rating Amidst Industry Reforms and Valuation Opportunities
Baird Adjusts CVS Health Price Target to $51 From $61, Maintains Neutral Rating
Wells Fargo Trim Price Target on CVS Health to $65 From $66
Leerink Partners Maintains CVS Health(CVS.US) With Hold Rating, Cuts Target Price to $51
Evercore Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $75
Evercore ISI Remains a Buy on CVS Health (CVS)
UBS Maintains CVS Health(CVS.US) With Hold Rating, Maintains Target Price $62
Morgan Stanley Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $63
Morgan Stanley Sticks to Its Buy Rating for CVS Health (CVS)
CVS Health Analyst Ratings
Deutsche Bank Upgrades CVS Health to Buy, Price Target at $66
Deutsche Bank Upgrades CVS Health(CVS.US) to Buy Rating, Raises Target Price to $66
CVS Health Price Target Raised to $80.00/Share From $73.00 by TD Cowen
CVS Health Is Maintained at Overweight by Piper Sandler
CVS Health Analyst Ratings
Piper Sandler Maintains CVS Health(CVS.US) With Buy Rating, Cuts Target Price to $64
Piper Sandler Sticks to Their Buy Rating for CVS Health (CVS)